ATRCHealthcare · Medical Instruments & SuppliesThe 10 Wall Street analysts covering AtriCure, Inc. hold a median 12-month price target of $60 — -8.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 3 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores AtriCure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (92): The business earns solid, repeatable profits on what it owns.
Value (68): The shares cost a lot relative to the profits and assets behind them.
Size (30): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ATRC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −8.3% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | Citizens | Maintains | Market Outperform | $52 → $68 |
| 12 Oct 2026 | BTIG | Maintains | Buy | $55 → $63 |
| 12 Oct 2026 | BTIG | Maintains | Buy | — |
| 2 Oct 2026 | Freedom Capital Markets | Downgrade | Hold | $43 → $57 |
| 2 Oct 2026 | Freedom Capital Markets | Downgrade | Hold | — |
| 2 Sept 2026 | Needham | Maintains | Buy | — |
| 2 Sept 2026 | Needham | Maintains | Buy | $45 → $64 |
| 27 Aug 2026 | Piper Sandler | Maintains | Overweight | $50 → $60 |
| 27 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Aug 2026 | BTIG | Maintains | Buy | — |
| 24 Aug 2026 | BTIG | Maintains | Buy | $45 → $55 |
| 28 July 2026 | UBS | Maintains | Buy | — |
| 28 July 2026 | UBS | Maintains | Buy | $55 → $50 |
| 6 May 2026 | Canaccord Genuity | Maintains | Buy | $53 → $55 |
| 6 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 18 Feb 2026 | BTIG | Reiterates | Buy | — |
| 18 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 18 Feb 2026 | Citizens | Maintains | Market Outperform | — |
| 18 Feb 2026 | Oppenheimer | Downgrade | Perform | — |
| 18 Feb 2026 | UBS | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ATRC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, AtriCure, Inc. returned +99.8% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 22% of US stocks
Cheaper than 16% of US stocks
Cheaper than 3% of US stocks
Higher than 59% of US stocks
Higher than 52% of US stocks
Higher than 89% of US stocks
Higher than 57% of US stocks
Higher than 51% of US stocks
Higher than 48% of US stocks
Higher than 52% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AtriCure, Inc. has a market value of $3.0B and an enterprise value of $3.0B.
Revenue in the twelve months to 30 June 2026: $569.6M. The latest quarter grew 12.8% year on year.
Net income over the same four quarters: $10.6M, a 1.9% net margin.
Diluted earnings per share, trailing twelve months: $0.21.
Free cash flow in the twelve months to 30 June 2026: $52.1M.
AtriCure, Inc. spent $12.3M on share buybacks and $0.0 on dividends in the twelve months to 30 June 2026.
Trailing P/E: 286.8×; forward P/E: 138.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AtriCure, Inc. employs 1,350 people — $422K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AtriCure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AtriCure reported better-than-expected third-quarter results, after which analysts boosted their forecasts, according to Benzinga.
Why it matters — The results and analyst forecast revisions are developments ATRC watchers may want to track.
AtriCure held its third-quarter 2026 earnings call on November 3, 2026. The excerpt lists company executives and participating analysts but does not include earnings results or management commentary.
Why it matters — The call is a source of quarterly updates for ATRC watchers, but the provided excerpt contains no business or financial details to assess.
AtriCure reported third-quarter 2026 revenue of $154.5 million, up 15% year over year. Growth in its U.S. open ablation, appendage management, and pain management businesses helped lift profitability.
Why it matters — The report gives ATRC watchers an update on revenue growth and the business areas that contributed to improved profitability.
Zacks Investment Research says AtriCure’s Q3 headline results for the quarter ended September 2026 can be assessed alongside key metrics, Wall Street estimates and year-ago actuals. The excerpt does not provide the results or comparisons.
Why it matters — These comparisons may help ATRC watchers evaluate the quarter, but the excerpt gives no specific metrics or outcomes.
AtriCure reported quarterly earnings of $0.17 per share, above the Zacks Consensus Estimate of $0.01. This compares with a loss of $0.01 per share a year earlier.
Why it matters — The per-share result exceeded consensus and improved from a loss in the year-ago quarter, providing an earnings update for ATRC watchers.
The 10 Wall Street analysts covering AtriCure, Inc. have a median 12-month price target of $60, with estimates ranging from $36 to $68. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering AtriCure, Inc., 7 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AtriCure, Inc. 96 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, AtriCure, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies -8.3% from the last close, and Ticker Nerd's factor model ranks AtriCure, Inc. 96 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AtriCure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATRC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $68 over the next 12 months.
AtriCure, Inc. returned +99.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain.
The most recent item we track (Benzinga, 4 Nov 2026): "AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results". AtriCure reported better-than-expected third-quarter results, after which analysts boosted their forecasts, according to Benzinga.
AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain. Its portfolio includes ablation systems, left atrial appendage exclusion devices, cryoablation products, and related surgical instruments used in cardiac, thoracic, and electrophysiology procedures. AtriCure’s products are designed for use by cardiothoracic surgeons, electrophysiologists, and medical centers that perform open, minimally invasive, and hybrid cardiac surgeries. The company serves healthcare providers in the United States and international markets, supporting procedure workflows in hospitals and specialized surgical settings. Founded in 2000 and headquartered in Mason, Ohio, AtriCure focuses on device-based therapies that address important needs in rhythm management and surgical pain control.
CEO Mr. Michael H. Carrel · 1,350 employees · United States · https://www.atricure.com
